Aurobindo Pharma Gets First USFDA Approval for Generic Anaesthesia

By By Rediff Money Desk, New Delhi
Sep 11, 2024 17:58
Aurobindo Pharma's subsidiary, Eugia Steriles, has received its first product approval from the USFDA for Lidocaine Hydrochloride Injection, a generic anaesthesia medication.
New Delhi, Sep 11 (PTI) Aurobindo Pharma on Wednesday said its unit has received the first product approval from the US Food and Drug Administration for a generic anaesthesia medication.

The new injectable facility of Eugia Steriles, a subsidiary of Eugia Pharma Specialities and a stepdown unit of the company, situated at Anakapalli District of Andhra Pradesh was inspected by the US FDA from March 28 to April 5 this year.

The plant has now received its first product approval from the USFDA for Lidocaine Hydrochloride Injection, Aurobindo Pharma said in a regulatory filing.

Shares of Aurobindo Pharma on Wednesday ended 0.74 per cent down at Rs 1,507.20 apiece on the BSE.
Source: PTI
Read More On:
aurobindo pharmausfdaeugia sterilesgeneric anaesthesialidocaine hydrochloride injection
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

Sebi Clears Pranav Adani in Insider Trading Case

Sebi clears Pranav Adani, Adani Group director, of insider trading charges related to...

Sebi Officials & Asset Disclosure: Privacy...

Sebi officials express privacy concerns over public asset disclosure. Pandey discusses...

New Labour Codes: Supply Chains, Wages, Skilling

New Labour Codes in India aim for frictionless supply chains, universal wage coverage,...

Fidelity Buys 6.3% Stake in Meesho

Fidelity International acquires a 6.3% stake in e-commerce firm Meesho. The stake is...

Wipro & Google Cloud Deploy Gemini AI

Wipro expands Google Cloud partnership to deploy Gemini AI across operations. Jointly...

IndiGo Faces Rs 59 Cr GST Penalty, Will Contest

IndiGo slapped with nearly Rs 59 crore GST penalty for FY21. Airline to contest the...

IRFC Loan Sanctions Target: Rs 60,000 Crore in Q3

IRFC aims to surpass Rs 60,000 crore in loan sanctions by Q3, says CMD Manoj Kumar...

Paytm Invests Rs 2,250 Cr in Payments Arm

Paytm invests Rs 2,250 crore in Paytm Payments Services. RBI approves payment...

Nephrocare IPO Subscribed 13.96 Times

Nephrocare Health Services' Rs 871-cr IPO was subscribed 13.96 times on closing....

PNB Housing Finance Appoints A K Shukla as MD &...

PNB Housing Finance names Ajai Kumar Shukla as MD & CEO, effective December 18, 2025....

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com